Evaluation of MET pathway activation by MET phosphorylation and more careful consideration of MET polysomy tumors in osimertinib-resistant EGFR-mutant NSCLC may help inform ongoing prospective studies of osimertinib plus savolitinib such as SAVANNAH (NCT03778229), ORCHARD (NCT03944772), and SAFFRON (NCT05261399). Here, MET is linked to non-small cell lung carcinoma.